Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients

American Journal of Transplantation

Volumn 11, Issue 1, 2011, Pages 66-76

  Ferguson, R ^a   Grinyo J ^b   Vincenti, F ^c   Kaufman, D B ^d   Woodle, E S ^e   Marder, B A ^f   Citterio, F ^g   Marks, W H ^h   Agarwal, M ⁱ   Wu, D ⁱ   Dong, Y ⁱ   Garg, P ⁱ  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^f PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

^g CATHOLIC UNIVERSITY   (Italy)

^h SWEDISH MEDICAL CENTER   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

Belatacept; calcineurin inhibitor; corticosteroid; immunosuppression; renal transplantation

Indexed keywords

BELATACEPT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE PYELONEPHRITIS; ADULT; ANEMIA; APHTHOUS STOMATITIS; ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; HYDRONEPHROSIS; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEINURIA; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RENAL GRAFT DYSFUNCTION; SIDE EFFECT; TREMOR; URINARY TRACT FISTULA; VIRUS INFECTION; WOUND DEHISCENCE;

ADRENAL CORTEX HORMONES; ADULT; CALCINEURIN; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS;

EID: 78650887509     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03338.x     Document Type: Article

References (46)

1. Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
2. Meier-Kriesche HU, Baliga R, Kaplan B,. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295.
3. Meier-Kriesche HU, Schold JD, Kaplan B,. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies Am J Transplant 2004; 4: 1289-1295.
4. Lietz K, Lewandowski Z, Lao M, et al,. Pretransplant and early posttransplant predictors of chronic allograft nephropathy in cadaveric kidney allograft-a single-center analysis of 1112 cases. Transpl Int 2004; 17: 78-88.
5. Nankivell BJ, Borrows RJ, Fung CL, et al,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
6. Ducloux D, Motte G, Kribs M, et al,. Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol 2002; 57: 409-413.
7. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
8. Kiberd B, Panek R,. Cardiovascular outcomes in the outpatient kidney transplant clinic: The Framingham risk score revisited. Clin J Am Soc Nephrol 2008; 3: 822-828.
9. Mathis AS, Dave N, Knipp GT, et al,. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004; 61: 565-585.
10. Roland M, Gatault P, Doute C, et al,. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008; 21: 523-530.
11. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506-1514.
12. Citterio F,. Steroid side effects and their impact on transplantation outcome. Transplantation 2001; 72: S75-S80.
13. Hjelmesaeth J, Hartmann A, Kofstad J, et al,. Tapering off prednisolone and cyclosporin the first year after renal transplantation: The effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829-835.
14. Veenstra DL, Best JH, Hornberger J, et al,. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829-839. (Pubitemid 29214678)
15. Pallardo LM, Oppenheimer F, Guirado L, et al,. Calcineurin inhibitor reduction based on maintenance immunosuppression with mycophenolate mofetil in renal transplant patients: POP study. Transplant Proc 2007; 39: 2187-2189.
16. Prasad GV, Nash MM, McFarlane PA, et al,. Renal transplant recipient attitudes toward steroid use and steroid withdrawal. Clin Transplant 2003; 17: 135-139.
17. Webster AC, Woodroffe RC, Taylor RS, et al,. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810-821.
18. Flechner SM, Goldfarb D, Modlin C, et al,. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
19. Flechner SM, Goldfarb D, Solez K, et al,. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883-892.
20. Kreis H, Cisterne JM, Land W, et al,. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260.
21. Vincenti F, Ramos E, Brattstrom C, et al,. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-1287.
22. Vincenti F, Schena FP, Paraskevas S, et al,. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307-316.
23. Rostaing L, Cantarovich D, Mourad G, et al,. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814.
24. Kumar MS, Heifets M, Moritz MJ, et al,. Safety and efficacy of steroid withdrawal two days after kidney transplantation: Analysis of results at three years. Transplantation 2006; 81: 832-839.
25. Hricik DE, Augustine JJ, Knauss TC, et al,. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2007; 83: 277-281.
26. Vincenti F, Monaco A, Grinyo J, et al,. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
27. Matas AJ, Kandaswamy R, Gillingham KJ, et al,. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5: 2473-2478.
28. Woodle ES, First MR, Pirsch J, et al,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
29. Flechner SM, Friend PJ, Brockmann J, et al,. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009-3014.
30. Knechtle SJ, Pirsch JD, Fechner H, et al,. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722-730.
31. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
32. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
33. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
34. Racusen LC, Solez K, Colvin RB, et al,. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
35. Levey AS, Coresh J, Greene T, et al,. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
36. Pei R, Wang G, Tarsitani C, et al,. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998; 59: 313-322.
37. Pei R, Lee JH, Shih NJ, et al,. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43-49.
38. Vaidya S, Cooper TY, Avandsalehi J, et al,. Improved flow cytometric detection of HLA alloantibodies using pronase: Potential implications in renal transplantation. Transplantation 2001; 71: 422-428.
39. Harada KM, Mandia-Sampaio EL, Sandes-Freitas TV, et al,. Risk factors associated with graft loss and patient survival after kidney transplantation. Transplant Proc 2009; 41: 3667-3670.
40. Go AS, Chertow GM, Fan D, et al,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
41. Manjunath G, Tighiouart H, Ibrahim H, et al,. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55. (Pubitemid 36044403)
42. Muntner P, He J, Hamm L, et al,. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753.
43. Buchler M, Caillard S, Barbier S, et al,. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531.
44. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al,. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin Transplant 2008; 22: 141-149.
45. Bluestone JA, Liu W, Yabu JM, et al,. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086-2096.
46. Heilman RL, Chakkera HA, Reddy KS, et al,. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression. Clin Transplant 2008; 22: 309-315.